No Data
No Data
ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish From Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Express News | ProMIS Neurosciences Inc Files for Resale From Time to Time of 56.5 Mln Common Shares of Co by Selling Stockholders - SEC Filing
ProMIS Neurosciences Granted US Patent 12,071,472 For "Methods Of Reducing Toxicity Induced By Amyloid Beta Oligomers Using Antibodies Specific To A-Beta Oligomers" In Alzheimer's Treatment
Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
ProMIS Neurosciences GAAP EPS of -$0.13
No Data